KIT and gastrointestinal stromal tumor: Moreover, some patients with GIST and systemic mastocytosis can benefit from the treatment of imatinib, dasatinib, or nilotinib due to the broad-spectrum selectivity of them against c-Kit, PDGFR, or Src.267,268 Mutations of these kinases can also drive the selection of appropriate inhibitors.